EQRx, Inc.

EQRx, Inc. filed an 8-K with the Securities and Exchange Commission on November 9, 2023, as the public entity resulting from its business combination with CM Life Sciences III Inc., which traded on Nasdaq under the ticker CMLT. CM Life Sciences III was a healthcare-focused special purpose acquisition company sponsored by CM Life Sciences that completed its IPO in 2021. EQRx, a biopharmaceutical company focused on developing and commercializing medicines at reduced prices, became publicly listed following the de-SPAC transaction. The November 2023 filing reflects ongoing public disclosure obligations in the biopharmaceutical sector. Sign up at SpacDesk for full filings, data, and analytics on EQRx and the broader SPAC universe.